Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Clinical trial NCT02879318 · COMPLETED
Trial details
- NCT number
- NCT02879318
- Sponsor
- Canadian Cancer Trials Group
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-07
- Primary completion
- 2020-08-03
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.